L6 ANSWER 1 OF 14 CAPLUS COPYRIGHT 2008 ACS on STN
TI Stability of Ogamma 100, a natural interferon pharmaceutical
AB .gamma.-Interferon in the form of a freeze-dried injectable prepn. (Ogamma 100) had an amino acid sequence of human .gamma.-interferon and was stable for .gtoreq.8 wk at room temp. under white fluorescent light, for .gtoreq.36 mo at 25.degree. in the dark. Upon dissoln. together with albumins and sucrose in distd. water, the .gamma.-interferon remained stable for .gtoreq.3 days at room temp. Combination of the prepn. with 1 % procaine.cntdot.HCl injection or 1 % lidocaine injection did not cause changes in soly., pH, activity, and osmotic pressure.

ACCESSION NUMBER: 1997:497606 CAPLUS
DOCUMENT NUMBER: 127:140449
ORIGINAL REFERENCE NO.: 127:26997a,27000a
TITLE: Stability of Ogamma 100, a natural interferon pharmaceutical
AUTHOR(S): Takeshita, Yoshiyuki; Takasugi, Masumitsu
CORPORATE SOURCE: Technical Div., Otsuka Pharmaceutical Co., Ltd., Japan
SOURCE: Kagaku Ryoho no Ryoiki (1997), 13(7), 1361-1364
CODEN: KRRYEI; ISSN: 0913-2384
PUBLISHER: Iyaku Janarusha
DOCUMENT TYPE: Journal
LANGUAGE: Japanese

L6 ANSWER 2 OF 14 CAPLUS COPYRIGHT 2008 ACS on STN
TI Stable .gamma.-interferon composition.
AB A frozen or lyophilized human .gamma.-interferon compn. in the substantial absence of inorg. salt, contains a monoamino aliph. amino acid. The human .gamma.-interferon includes natural interferon and interferon obtained by recombinant DNA technol. Thus, 0.5 mL aq. soln. contg. 15 mg glycine was added to 1 mL human .gamma.-interferon soln. having a potency of 2.4 .times. 106 IU/mL and contg. 3 mg glutathione (reduced form). Then, the mixt. was lyophilized in a vial. When the lyophilizate was reconstituted with 1 mL of distd. water for injection, the soln. was clear and showed 100% residual potency.

ACCESSION NUMBER: 1986:485179 CAPLUS
DOCUMENT NUMBER: 105:85179
ORIGINAL REFERENCE NO.: 105:13717a,13720a
TITLE: Stable .gamma.-interferon composition.
INVENTOR(S): Akagi, Yasaburo; Miura, Yasumoto; Hoshino, Tetsuo
PATENT ASSIGNEE(S): Takeda Chemical Industries, Ltd. , Japan
SOURCE: Eur. Pat. Appl., 35 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 168008	A2	19860115	EP 1985-108409	19850706
EP 168008	A3	19861230		
R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE				
WO 8600531	A1	19860130	WO 1984-JP352	19840710
W: MC				
WO 8606080	A1	19861023	WO 1985-JP190	19850412
W: MC				
JP 61044826	A	19860304	JP 1985-148093	19850704

PRIORITY APPLN. INFO.: WO 1984-JP352 A 19840710
WO 1985-JP190 A 19850412

L6 ANSWER 3 OF 14 CAPLUS COPYRIGHT 2008 ACS on STN
TI Preparation containing stabilized physiologically active substance
AB The title prepn. comprises a modified gelatin and a physiol. active substance made of a basic protein or polypeptide, i.e. .gamma.-interferon, obtained from a microorganism by recombinant DNA technol. The chem. modified gelatin, used as a stabilizer, prevents a reagglutination of .gamma.-interferon so as to provide a prepn. for parenteral administration. Thus, .gamma .-interferon was dissolved in the chem. modified gelatin (principal component of Haemaccel), and the soln. was passed through a sterilization filter. The filtrate was freeze-dried and its antiviral effect was measured.
ACCESSION NUMBER: 1986:136070 CAPLUS
DOCUMENT NUMBER: 104:136070
ORIGINAL REFERENCE NO.: 104:21407a,21410a
TITLE: Preparation containing stabilized physiologically active substance
INVENTOR(S): Terano, Yoshitake
PATENT ASSIGNEE(S): Suntory, Ltd., Japan
SOURCE: Eur. Pat. Appl., 21 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 162332	A1	19851127	EP 1985-105092	19850426
EP 162332	B1	19890719		
R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE				
JP 60228422	A	19851113	JP 1984-84990	19840426
JP 04081573	B	19921224		
US 4659570	A	19870421	US 1985-727261	19850425
AT 44652	T	19890815	AT 1985-105092	19850426

PRIORITY APPLN. INFO.: JP 1984-84990 A 19840426
EP 1985-105092 A 19850426

L6 ANSWER 4 OF 14 CAPLUS COPYRIGHT 2008 ACS on STN
TI Interferon solubilization with amino acids
AB Interferon is solubilized by addn. of 5 .times. 10-6 - 5 .times. 10-3 mol amino acid/106 units interferon. The amino acid may be arginine, histidine, lysine, hydroxylysine, ornithine, glutamine, .gamma.-aminobutyric acid, .epsilon.-aminocaproic acid, or a salt of these compds. Thus, 5 mg serum albumin, 5 mg NaCl, 30 mg arginine-HCl, and 3 .times. 106 units of .gamma.-interferon were mixed with 2 mL H2O, and freeze-dried. The product was dissolved in 5 mL H2O, held 6 h at 25.degree., and the absorbance was measured at 400 nm. The amt. of .gamma.-interferon that remained in soln. was 98%. This solubilization may be used to facilitate the isolation and purifn. of interferon produced by recombinant DNA technol.
ACCESSION NUMBER: 1986:174635 CAPLUS
DOCUMENT NUMBER: 104:174635
ORIGINAL REFERENCE NO.: 104:27549a,27552a
TITLE: Interferon solubilization with amino acids
INVENTOR(S): Kato, Yasuki; Hayakawa, Eiji; Furuya, Kunitoshi; Kondo, Akira

PATENT ASSIGNEE(S): Kyowa Hakko Kogyo Co., Ltd. , Japan
SOURCE: Eur. Pat. Appl., 14 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 163111	A2	19851204	EP 1985-104849	19850422
EP 163111	A3	19870930		
EP 163111	B1	19901003		
R: DE, FR, GB, IT				
JP 60243028	A	19851203	JP 1984-86972	19840428
JP 05058000	B	19930825		
CA 1264665	A1	19900123	CA 1985-479841	19850423
US 4675183	A	19870623	US 1985-726971	19850425

PRIORITY APPLN. INFO.: JP 1984-86972 A 19840428

L6 ANSWER 5 OF 14 CAPLUS COPYRIGHT 2008 ACS on STN
TI Gamma interferon composition
AB Stable .gamma.-interferon (I) compns. comprise in addn. to I at least 3 mg albumin or 5 mg of a sugar such as a mono-, or disaccharide, or sugar alc./1 .times. 10-2-1 .times. 10-7 units I as a stabilizer. In the stabilized compn. I is not inactivated during lyophilization of the aq. soln. contg. I and the storage stability of the dry prepn. formed by lyophilization is improved. Thus, a lyophilized prepn. contg. sucrose [57-50-1] at 10 mg/mL I which had an activity immediately before lyophilization of 100% had 96% activity after lyophilization and 90% after 6 mo storage at room temp. compared to 32% for I without stabilizer.
ACCESSION NUMBER: 1985:154791 CAPLUS
DOCUMENT NUMBER: 102:154791
ORIGINAL REFERENCE NO.: 102:24269a,24272a
TITLE: Gamma interferon composition
INVENTOR(S): Noda, Munehiro; Fujita, Takaaki; Morise, Hiroshi; Arimura, Hirofumi; Suyama, Tadakazu
PATENT ASSIGNEE(S): Green Cross Corp., Japan
SOURCE: Eur. Pat. Appl., 13 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 133767	A2	19850306	EP 1984-304992	19840723
EP 133767	A3	19861217		
EP 133767	B1	19910403		
R: BE, DE, FR, GB, NL, SE				
JP 60034919	A	19850222	JP 1983-143484	19830804
JP 60048933	A	19850316	JP 1983-157560	19830829
JP 06051641	B	19940706		
CA 1223207	A1	19870623	CA 1984-459960	19840730
ES 534815	A1	19850601	ES 1984-534815	19840802

PRIORITY APPLN. INFO.: JP 1983-143484 A 19830804
JP 1983-157560 A 19830829

L6 ANSWER 6 OF 14 CAPLUS COPYRIGHT 2008 ACS on STN

TI Stabilized injection solutions containing nonlyophilized gamma-interferons

AB A liq. pharmaceutical compn. comprises an effective amt. of nonlyophilized .gamma.-interferon. The compn. further includes a buffer capable of maintaining the pH within 4-6, polyhydric sugar alcs. as stabilizer, and a nonionic detergent. The relative shelf-life for the liq. contg. 2 mg/mL .gamma.-interferon, mannitol, and succinate buffer was 10 days as compared to 1 day for the lyophilized formulation.

ACCESSION NUMBER: 1990:62635 CAPLUS
DOCUMENT NUMBER: 112:62635
ORIGINAL REFERENCE NO.: 112:10626h,10627a
TITLE: Stabilized injection solutions containing nonlyophilized gamma-interferons
INVENTOR(S): Hwang-Felgner, Jiin Yu; Jones, Richard E.; Maher, James F.
PATENT ASSIGNEE(S): Genentech, Inc., USA
SOURCE: PCT Int. Appl., 15 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 8904177	A1	19890518	WO 1988-US3883		19881101
W: AU, DK, FI, HU, JP, KR, NO					
RW: AT, BE, CH, DE, FR, GB, IT, LU, NL, SE					
IL 88233	A	19930818	IL 1988-88233		19881030
AU 8827245	A	19890601	AU 1988-27245		19881101
AU 621327	B2	19920312			
EP 386106	A1	19900912	EP 1988-910211		19881101
EP 386106	B1	19940302			
R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE					
JP 03500882	T	19910228	JP 1988-509401		19881101
JP 2732877	B2	19980330			
AT 102048	T	19940315	AT 1988-910211		19881101
ZA 8808249	A	19900725	ZA 1988-8249		19881103
DD 289470	A5	19910502	DD 1988-321429		19881103
CA 1335176	C	19950411	CA 1988-582102		19881103
US 5151265	A	19920929	US 1990-514392		19900425
PRIORITY APPLN. INFO.:			US 1987-116434	A	19871103
			EP 1988-910211	A	19881101
			WO 1988-US3883	A	19881101

L6 ANSWER 13 OF 14 USPATFULL on STN

TI MEDICAMENT ADMINISTRATION SYSTEM

AB A pharmaceutical formulation to be administered by a medicament administration device, which can maintain high stability of a biological active substance, is provided. In preparing the pharmaceutical formulation to be administered via mucous membrane, particularly a pharmaceutical formulation to be inhaled by utilizing a jet nebulizer, an ultrasonic nebulizer, a metered dose inhaler, or a dry powder inhaler, the adoption of the step of contacting the biological active substance with liposomes or microspheres in an aqueous medium enables the substance to be highly stabilized.

ACCESSION NUMBER: 2001:237498 USPATFULL
TITLE: MEDICAMENT ADMINISTRATION SYSTEM
INVENTOR(S): NAGATA, SHUNJI, ASHIYA-SHI, Japan
KANAOKA, ERI, OSAKA-SHI, Japan

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20010055610	A1	20011227
APPLICATION INFO.:	US 1999-424959	A1	19991206 (9)
	WO 1998-JP2374		19980529
			None PCT 102(e) date

	NUMBER	DATE
PRIORITY INFORMATION:	JP 1997-148346	19970606

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: WENDEROTH LIND & PONACK, 2033 K STREET NW, SUITE 800, WASHINGTON, DC, 20006
NUMBER OF CLAIMS: 22
EXEMPLARY CLAIM: 1
LINE COUNT: 917
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d his

(FILE 'HOME' ENTERED AT 18:27:12 ON 16 AUG 2008)

FILE 'CAPLUS, MEDLINE, USPATFULL, BIOSIS' ENTERED AT 18:27:35 ON 16 AUG 2008

L1 178136 S (INTERFERON (4A) GAMMA)
L2 225 S L1 (P) ((FREEZE (3A) DR?) OR LYOPHILIZ? OR CRYODESSIC?)
L3 23 S L2 (P) (STABILIZER OR STABILISER OR (AMINO(W)ACID) OR VALINE
L4 14 S L3 NOT PD>20021231
L5 14 DUP REM L4 (0 DUPLICATES REMOVED)
L6 14 FOCUS L5 1-

=> d que L3
L1 178136 SEA (INTERFERON (4A) GAMMA)
L2 225 SEA L1 (P) ((FREEZE (3A) DR?) OR LYOPHILIZ? OR CRYODESSIC?)
L3 23 SEA L2 (P) (STABILIZER OR STABILISER OR (AMINO(W) ACID) OR VALINE OR LEUCINE OR ISOLEUCINE OR DIISOLEUCINE OR DILEUCINE OR TRILEUCINE OR TRIISOLEUCINE)